Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 1
2009 1
2010 1
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

3 results
Results by year
Filters applied: . Clear all
Page 1
Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease.
Mosca L, Grady D, Barrett-Connor E, Collins P, Wenger N, Abramson BL, Paganini-Hill A, Geiger MJ, Dowsett SA, Amewou-Atisso M, Kornitzer M. Mosca L, et al. Stroke. 2009 Jan;40(1):147-55. doi: 10.1161/STROKEAHA.108.518621. Epub 2008 Oct 23. Stroke. 2009. PMID: 18948611 Free PMC article. Clinical Trial.
No significant subgroup interactions were found except that there was a higher incidence of stroke associated with raloxifene use among current smokers. CONCLUSIONS: In postmenopausal women at increased risk for coronary events, the incidences of ve
No significant subgroup interactions were found except that there was a higher incidence of stroke associated with raloxifene
Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.
Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK; Raloxifene Use for The Heart (RUTH) Trial Investigators. Barrett-Connor E, et al. N Engl J Med. 2006 Jul 13;355(2):125-37. doi: 10.1056/NEJMoa062462. N Engl J Med. 2006. PMID: 16837676 Free article. Clinical Trial.
There was no significant difference in the rates of death from any cause or total stroke according to group assignment, but raloxifene was associated with an increased risk of fatal stroke (59 vs. 39 events; hazard ratio, 1.49; 95 percent …
There was no significant difference in the rates of death from any cause or total stroke according to group assignment, but …
Effect of Raloxifene on all-cause mortality.
Grady D, Cauley JA, Stock JL, Cox DA, Mitlak BH, Song J, Cummings SR. Grady D, et al. Am J Med. 2010 May;123(5):469.e1-7. doi: 10.1016/j.amjmed.2009.12.018. Am J Med. 2010. PMID: 20399327 Clinical Trial.
OBJECTIVE: Raloxifene, a selective estrogen receptor modulator, reduces osteoporosis and invasive breast cancer risk but increases risk for venous thromboembolism and fatal stroke in women with or at high risk for coronary h …
OBJECTIVE: Raloxifene, a selective estrogen receptor modulator, reduces osteoporosis and invasive breast cancer risk but in